Key result
Combination treatment with darbepoetin and G-CSF safely and more efficiently mobilized and recruited proangiogenic cells in higher purity than G-CSF alone in patients with AMI.
Why the study?
Does combination treatment with darbepoetin and G-CSF improve the mobilization of proangiogenic cells compared to G-CSF alone in patients with acute myocardial infarction?
Population
60 patients with acute myocardial infarction (AMI)
Comparison
Combination treatment with darbepoetin and G-CSF vs G-CSF alone (10 μg/kg/day for 3 days)
Design
RCT, 2:1 ratio
Authors
Loading...
Combination therapy improves mobilization in AMI; extends cell-recruitment data but leaves clinical outcome trials needed.
RCT (n=60)
2:1 ratio
Does combination treatment with darbepoetin and G-CSF improve the mobilization of proangiogenic cells compared to G-CSF alone in patients with acute myocardial infarction?
Combination therapy with darbepoetin and G-CSF safely and more efficiently mobilizes proangiogenic cells than G-CSF alone in patients with acute myocardial infarction.
Kang et al. (2012) conducted an RCT in Acute myocardial infarction (AMI) (n=60). Darbepoetin and G-CSF vs. G-CSF alone was evaluated on Safety and peripheral blood stem/progenitor cell (PBSC) mobilizing effects. Combination treatment with darbepoetin and G-CSF safely and more efficiently mobilized and recruited proangiogenic cells in higher purity than G-CSF alone in patients with AMI.